UroGen Pharma Ltd. (URGN) Return on equity 2016–2021
UroGen Pharma Ltd. (URGN) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-1317.2%FY2021 · since FY2016: -11.9% → -1317.2%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2021 | -1317.2% | -1183.9 pp |
| FY2020 | -133.3% | -75.0 pp |
| FY2019 | -58.3% | +25.7 pp |
| FY2018 | -84.0% | -54.8 pp |
| FY2017 | -29.2% | -17.3 pp |
| FY2016 | -11.9% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More URGN financial trends
URGN RevenueURGN Net incomeURGN Net marginURGN Gross profitURGN Gross marginURGN Operating incomeURGN Operating marginURGN Operating cash flowURGN Free cash flowURGN Capital expendituresURGN Stock buybacksURGN Dividends paidURGN Total assetsURGN Total liabilitiesURGN Shareholders’ equityURGN overview →